V ascular smooth muscle cells (SMC) retain the ability to dedifferentiate to a synthetic phenotype characterized by proliferation, migration, loss of contractile protein expression, and enhanced protein and matrix synthesis. This not only allows for vascular growth and repair but also contributes to intimal hyperplasia in response to injury. 1 The use of drugeluting stents (DES) coated with the mTORC1 (mechanistic target of rapamycin complex 1) inhibitor rapamycin or its analogs has dramatically reduced intimal hyperplasia after coronary artery interventions, 2,3 but adverse effects limit the use of rapamycin for other types of vascular disease in which local delivery is not feasible. Thus, understanding the mechanisms of action of mTORC1 inhibition has important therapeutic implications for diseases involving SMC phenotypic modulation, including atherosclerosis, transplant arteriopathy, and aneurysm. 1 The AKT (protein kinase B) signaling pathway is activated by insulin, growth factors, and cytokines and regulates many critical cellular functions, including cell metabolism, survival, proliferation, differentiation, and migration. 4 There are 3 members of the AKT family of serine/threonine protein kinases, encoded by separate genes. The AKT1, AKT2, and AKT3 isoforms share >80% homology overall, with 90% conservation in the kinase domains, 5 but emerging evidence suggests that there are distinct functions for these isoforms.
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The mTORC1 pathway is critical in the SMC in response to vascular injury in vivo, 2 and rapamycin inhibits SMC proliferation and migration in vitro. [12] [13] [14] Our previous work suggests that rapamycin is a particularly effective therapeutic because it also promotes SMC differentiation characterized by transcriptional induction of smooth muscle contractile proteins, including MYH11 (smooth muscle myosin heavy chain), CNN1 (calponin 1), ACTA2 (smooth muscle α-actin), TAGLN (transgelin, or smooth muscle protein 22-alpha), and others. [15] [16] [17] The mTORC1 pathway provides inhibitory inputs to insulin and IGF-1 (insulin-like growth factor 1) signaling to PI3K (phosphoinositide 3-kinase) in many cell types. These are mediated, in part, at the level of mTORC1-dependent inhibitory phosphorylation of IRS-1 (insulin receptor substrate 1), which diminishes signaling to PI3K/AKT. 16, 18 Consequently, mTORC1 inhibition with rapamycin or other agents can activate AKT by disrupting this classical negative feedback loop. 18, 19 Interestingly, we found that in SMC, rapamycin promotes a specific activation of the AKT2 isoform that is required for rapamycin-induced SMC differentiation, including contractile protein expression and myocyte morphology, in vitro. 16 Although AKT2 is essential in insulinresponsive tissues, 20 little is known about the functions and unique substrates of AKT2 in SMC in vivo. AKT phosphorylation of FOXO (forkhead box O) family transcription factors promotes their inactivation by nuclear exclusion and binding to 14-3-3 proteins, 4, 21 but AKT isoform-specific regulation of FOXO factors is not well defined. In this study, we assess the roles of AKT isoforms in intimal hyperplasia and the therapeutic effects of rapamycin in vivo and identify FOXO4 as a critical substrate for AKT2 in transcriptional regulation of MYOCD, a master regulator of SMC phenotype. 22 
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Genetic Loss of AKT2 Promotes Severe Intimal Hyperplasia and Prevents the Therapeutic Effect of Rapamycin
We have previously found that rapamycin treatment selectively activates the AKT2 isoform in cultured SMC and that this signaling is required for rapamycin-induced SMC differentiation in culture, upregulating transcription of contractile proteins in an AKT2-dependent manner. 15, 16 To determine whether AKT2 is an essential effector mediating the therapeutic effect of rapamycin on intimal hyperplasia in vivo, we subjected mice with global deletion of Akt2 to femoral artery wire denudation injury. Neointimal hyperplasia was detected in wild-type (WT) mice at 21 days post-injury, but the Akt2 −/− mice exhibited a more severe intimal hyperplastic response ( Figure 1A) , consistent with our previous findings. 23 Consistent with its efficacy as an antirestenotic agent, systemic injection of rapamycin had a potent therapeutic effect in WT mice, significantly reducing neointimal hyperplasia and cellular proliferation. However, rapamycin treatment failed to reduce intimal hyperplasia (Figure 1A) or proliferation in the Akt2 −/− mice ( Figure IIA in the online-only Data Supplement). Although global deletion of Akt2 leads to a diabetic phenotype, 20 we verified that mice had normal blood glucose at the time injury experiments were conducted (8-10 weeks of age; Figure III in the online-only Data Supplement). AKT2 has also been reported to influence extracellular matrix remodeling. 24 Trichrome staining did not reveal obvious differences in collagen post-injury in Akt2 −/− compared with WT (Figure IV in the online-only Data Supplement).
As multiple cell types can influence the injury response, we assessed intimal hyperplasia in mice with smooth musclespecific deletion of Akt2 (Myh11cre-Akt2 Figure  IVA and IVC in the online-only Data Supplement), consistent with our previous in vitro findings. 16 Rapamycin also failed to inhibit intimal hyperplasia and cell proliferation in the SM-Akt2 −/− mice ( Figure 1B ; Figure IIB in the online-only Data Supplement), demonstrating that smooth muscle AKT2 limits the severity of intimal hyperplasia and is required for the rapamycin therapeutic response.
In our previous in vitro studies, AKT1 knockdown did not impair the ability of rapamycin to promote SMC differentiation, and overexpression of AKT2, but not of AKT1, was sufficient to induce contractile protein expression. 16 We found that mice with global germ-line deletion of Akt1 exhibited a profound occlusive thrombotic response after femoral artery denudation, leading to hindlimb ischemia and tissue necrosis (Table) , consistent with the critical role of AKT1 in endothelial cell survival and migration. 7 Because this severe thrombotic response precludes evaluation of a smooth muscle phenotype, we subjected mice with smooth muscle-specific deletion of Akt1 (Myh11creER proliferation and migration in vitro. 25 Our data reveal that AKT1 and AKT2 play opposing roles, with AKT1 promoting and AKT2 limiting the SMC intimal hyperplastic response.
Although the arterial denudation injury responses revealed dramatic, opposing phenotypes with deletion of Akt1 or Akt2, there were modest differences in the vessels of these mice in the uninjured state. The femoral artery medial areas did not differ from controls in the uninjured 
AKT1 and AKT2 Have Opposing Effects on SMC Phenotypic Modulation In Vitro
Given the opposing effect on intimal hyperplasia of these highly homologous AKT isoforms in response to vascular injury, we compared their effects on important aspects of SMC phenotype and rapamycin response in culture using knockdown and knockout approaches ( Figure 2 ; Figures IX and X in the online-only Data Supplement). We have previously shown that rapamycin treatment induces a differentiated, contractile morphology in SMC, which is reflected in a reduction in 2-dimensional cell area. 15 AKT1 and AKT2 exerted opposite effects on SMC morphology in this assay: compared with human coronary artery SMC (hCASMC) transfected with control siRNA, which exhibited a dedifferentiated phenotype, knockdown of AKT1 in hCASMC induced a contractile morphology (spindle shaped, smaller 2-dimensional area), , or Akt2 −/− mice were subjected to femoral artery wire denudation injury as described in the Materials and Methods in the online-only Data Supplement. At 21 d post-injury, vessels were evaluated for morphometry, incidence of thrombosis, and toe necrosis. *P<0.01 (χ 2 test). . Reduced area reflects a more contractile, differentiated morphology. B, Cell proliferation was measured using the xCELLigence system. Two thousand cells were plated per well (n=3 biological replicates were each assayed in duplicate). After starvation for 8 to 12 h, proliferation in 10% fetal bovine serum (FBS) medium was recorded at the indicated times. C, Control and knockdown cells were subjected to scratch migration assay. Area migrated (mm 2 ) was measured after 8-h incubation in media containing 0.5% FBS (n=5), 10% FBS (n=6), or 0.5% FBS plus 10 ng/mL platelet-derived growth factor (PDGF)-BB (n=6). (representative micrographs shown in Figure XA in the online-only Data Supplement). D, Control and knockdown cells were subjected to traditional Boyden chamber transwell migration assay. 10 ng/mL PDGF-BB was used as a chemoattractant. Cells were pretreated with ethanol (vehicle) or 50 nmol/L rapamycin (n=6 vehicle, n=9 rapamycin). Data are presented as mean±SEM. *P<0.05, **P<0.01, ***P<0.001.
whereas AKT2 knockdown promoted a more dedifferentiated morphology (rhomboid morphology, larger 2-dimensional area) and blocked rapamycin-induced morphological differentiation (Figure 2A ; Figure IXA and IXB in the online-only Data Supplement). Interestingly, the AKT1 phenotype seems to be dominant when both AKT1 and AKT2 are knocked down because cell size is the same as with siAKT1 alone. However, the reduction in AKT2 expression prevents the response to rapamycin in this context (Figure 2A) .
Because rapamycin is antiproliferative in many cell types, we compared the effects of AKT1 and AKT2 on proliferation in cultured SMC. AKT1 and AKT2 exerted opposite effects on SMC proliferation: siAKT1 reduced, whereas siAKT2 augmented, hCASMC or human aortic SMC proliferation in response to stimulation with 10% serum ( Figure 2B ; Figure  XIIA in the online-only Data Supplement). Knocking down both isoforms mimicked the phenotype of the control siRNA ( Figure 2B ). The opposing effects of these isoforms on proliferation were also seen in aortic SMC isolated from Akt1 or Akt2 knockout mice in the absence or presence of rapamycin ( Figure IXC and IXD in the online-only Data Supplement). Similar trends were observed with multiple assays of SMC migration. In scratch and Boyden chamber assays, siAKT1 inhibited, whereas siAKT2 augmented, the hCASMC migration responses to platelet-derived growth factor-BB and serum ( −/− and Akt2 −/− mouse embryonic fibroblasts. 26 We observed similar effects in hCASMC, where AKT1 knockdown led to diminished platelet-derived growth factor-BB-induced phosphorylation of PAK1 at several sites associated with its activity 27, 28 and reduced RAC1 activity, whereas AKT2 knockdown had the opposite effect ( Figure XI in the online-only Data Supplement).
AKT2 Promotes MYOCD Expression Through Inhibition of FOXO4
Assessing multiple parameters, we found that AKT2 promotes the differentiated SMC phenotype, whereas AKT1 promotes a dedifferentiated phenotype, and that AKT2 is required for the beneficial effects of rapamycin on contractile morphology, proliferation, and migration. Because we have reported that AKT2 is required for rapamycin-induced contractile protein expression, 16 we next assessed transcriptional regulators that might mediate the potent effects of rapamycin and AKT2 on SMC differentiation. We now report that rapamycin induces MYOCD mRNA expression ( Figure 3A) . Notably, both basal and rapamycin-induced expression of MYOCD depended on AKT2 but not on AKT1 ( Figure 3A ; Figure XIIB in the online-only Data Supplement). This was also true for the contractile protein markers of differentiation, MYH11 and TAGLN ( Figure 3A ; Figure XI in the online-only Data Supplement), which are known to be regulated by MYOCD. 22 (Efficiency of AKT1 and AKT2 knockdown is confirmed in Figure 3B ; Figures IXA and XIIB in the online-only Data Supplement.) The induction of MYOCD by rapamycin occurs at the level of transcription because rapamycin treatment did not affect MYOCD mRNA half-life assessed in the presence of actinomycin D ( Figure 3C ).
We next sought to determine how AKT2 might regulate the expression of MYOCD. The FOXO family proteins have long been known to be AKT substrates, with this phosphorylation regulating their subcellular localization, 4, 21 and FOXO proteins have been implicated in SMC phenotypic modulation. [29] [30] [31] [32] We now demonstrate that rapamycin promotes phosphorylation of FOXO4 at Ser193 in hCASMC and that this phosphorylation requires AKT2 but not AKT1 ( Figure 4A and 4B). AKT phosphorylates FOXO4 at 3 sites, including S193, which promotes FOXO4 nuclear exclusion. 21 We find that rapamycin promotes nuclear exclusion of FOXO4 in control hCASMC or with AKT1 knockdown but not with AKT2 knockdown (Figure 4C and 4D) . AKT-dependent phosphorylation also promotes ubiquitination and degradation of FOXO4. 33 Consequently, we observe an increase in total FOXO4 levels ( Figure 4A and 4B) .
FOXO4 knockdown inhibits contractile protein expression, 30, 32 and a recent report found that FOXO4 knockdown could increase the activity of a mouse Myocd promoter-reporter construct. This study also found that FOXO3a could bind to 2 FOXO response elements in the human MYOCD promoter in a chromatin immunoprecipitation polymerase chain reaction assay. 32 Using a more sensitive chromatin immunoprecipitation quantitative polymerase chain reaction assay, we find that endogenous FOXO4 binds to 2 FOXO elements in the proximal region of the human MYOCD promoter and that this binding is reduced by half after rapamycin treatment ( Figure 5A ; Figures XIIIA and XIIIB in the online-only Data Supplement). Notably, FOXO4 binding was strongly induced with AKT2 knockdown, and rapamycin failed to inhibit FOXO4 binding under these conditions ( Figure 5A ). AKT1 knockdown did not significantly alter FOXO4 binding to the MYCOD promoter and did not impair the ability of rapamycin to inhibit FOXO4 binding to these elements ( Figure 5A ). Furthermore, we find that FOXO4 knockdown in hCASMC increases MYOCD and MYH11 mRNA expression to a similar extent as rapamycin, whereas AKT2 knockdown dramatically reduces MYOCD and MYH11 expression. Notably, FOXO4 knockdown attenuates the effect of AKT2 knockdown on MYOCD and MYH11 expression, suggesting that FOXO4 is an important effector of AKT2 signaling ( Figure 5B) . A promoter-reporter assay using Myocd promoter constructs ( Figure XIIIC in the online-only Data Supplement) 34 provided additional evidence of Myocd regulation by AKT2/FOXO4 in HEK293 (human embryonic kidney cells 293) cells and hCASMC ( Figure 5C and 5D, respectively): AKT2 overexpression transactivated the fulllength promoter-reporter but not a truncated reporter lacking FOXO-binding elements in HEK293 cells ( Figure 5C ). Accordingly, in hCASMC, AKT2 overexpression increased, whereas FOXO4 overexpression repressed, Myocd promoterreporter activity ( Figure 5D ). FOXO4 coexpression attenuated the transactivation by AKT2 ( Figure 5C ). Consistent with the AKT2 regulation of FOXO4 in hCASMC, systemic delivery of rapamycin induced FOXO4 phosphorylation and Myocd mRNA expression in normal mouse aorta, but these effects were entirely prevented in aortas of Akt2 −/− mice ( Figure 6 ).
Discussion
We report that the therapeutic effects of rapamycin, a potent antirestenotic agent, are mediated by AKT2 signaling in smooth muscle. We further demonstrate that the highly homologous AKT1 and AKT2 isoforms exert opposing effects on SMC phenotype in vivo and in vitro. These phenotypes are consistent among mouse injury models, mouse aortic knockout SMC, and human aortic and coronary artery SMC with siRNA knockdown. Additionally, we identify FOXO4 as an AKT2-specific substrate that regulates the transcription of MYOCD. As a master regulatory transcriptional cofactor, MYOCD coordinately regulates many aspects of SMC phenotype, including contractile protein expression and proliferation. 22 Our work identifies AKT2 as a key effector of mTORC1 inhibition in vivo. Rapamycin analogs are highly efficacious in preventing intimal hyperplasia post-angioplasty in patients. 2, 3 Previous studies identified an antiproliferative effect of rapamycin in SMC, 12, 13 but other antiproliferative agents and approaches were not successful DES therapeutics. 35 We have posited that rapamycin is a potent antihyperplastic agent because of its pleiotropic effects, arresting both proliferation and migration 36 while also inducing a differentiated program of gene expression. [15] [16] [17] We determined that rapamycin selectively activated AKT2 in cultured SMC and that this signal was required to induce contractile protein expression in vitro. 16 We now validate these findings in vivo, demonstrating a dramatic phenotype in the SM-Akt2 −/− mice. These mice have a severe intimal hyperplastic response after arterial injury compared with controls. Importantly, the ability of rapamycin to almost completely prevent intimal hyperplasia in WT mice is lost in the SM-Akt2 −/− mice. Although rapamycin also has immunosuppressant actions, the smooth muscle-specific Akt2 knockout phenotype indicates that the major effect on neointimal hyperplasia is mediated by SMC and not circulating cells.
AKT1 and AKT2 are highly homologous and have been found to have many common substrates. There is some functional redundancy as germ-line knockouts of individual Akt isoforms are viable, but distinct phenotypes hint at unique functions. 6 The Akt1 knockout exhibits a small-size phenotype, whereas the Akt2 knockout develops diabetes mellitus. 20, 37 Our studies identify nonoverlapping and, in fact, opposite functions for these isoforms in SMC ( Figure XIVA in the online-only Data Supplement). We note that AKT1 is required for SMC proliferation and migration and is associated with the dedifferentiated phenotype, whereas AKT2 exerts antiproliferative, antimigratory effects and promotes expression of contractile proteins and contractile morphology. Our data concur with studies in mouse embryonic fibroblasts from Akt1 or Akt2 knockout mice that found that AKT1 promotes, whereas AKT2 inhibits, migration through differential signaling to the Rac/PAK pathway. 26 Interestingly, studies in cancer cell lines also find opposing roles for AKT isoforms in migration, but the roles are reversed relative to SMC. 38, 39 A diversity of roles for AKT isoforms is emerging in different cancer types, and understanding these isoform-specific roles will be essential for optimal utilization of the AKT inhibitors already in clinical trials. 40 As has been reported by other investigators in fibroblasts 41, 42 and in SMC in our previous publications, 16, 31 we find that transient AKT1 knockdown increases expression and activity of AKT2 in hCASMC ( Figure 4A ). This data suggest that there is a balance between AKT isoforms, with AKT1 imposing a brake on AKT2 expression. It is possible that some of the effects of AKT1 knockdown in culture, including increased contractile protein expression, may be attributable to the compensatory increase in AKT2. However, SMC isolated from SM-Akt1 −/− mice do not exhibit upregulation of AKT2, yet exhibit dramatic phenotypes consistent with the knockdown phenotypes observed in vivo, suggesting that AKT1 has functions in regulation of SMC phenotype independent of any regulation of AKT2.
Multiple factors may account for AKT isoform-specific functions among cell types and tissues, including differing expression levels, subcellular localizations, cell type-specific expression of substrates and regulatory proteins, and cross talk with other signaling pathways. AKT1 and AKT2 are expressed in blood vessels at similar levels, 7 but AKT1 is the predominant isoform in endothelial cells. 8 Many studies have determined that AKT1 is essential for endothelial functions. [6] [7] [8] [9] [10] [11] Our study supports a key role for AKT1 in endothelium because germ-line deletion of Akt1 resulted in occlusive thrombosis after vascular injury. It is likely that this is because of failure to re-endothelialize the lesion because AKT1 is required for endothelial cell survival, proliferation, and migration, 7 and Akt1 deletion has little effect on platelet function. 43 Although this severe phenotype precluded assessment of intimal hyperplasia, we found that the smooth muscle-specific Akt1 knockout was completely resistant to intimal hyperplasia, indicating an essential role for SMC AKT1 in this vascular remodeling. Increased apoptosis and necrotic core area were found in atherosclerotic models with smooth muscle-specific deletion of Akt1, suggesting that AKT1 promotes SMC survival in this context. 25, 44 Studies using inducible, constitutively active AKT1 confirm an antiapoptotic role in smooth muscle remodeling.
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AKT1 and AKT2 are reportedly expressed at similar levels in SMC. 8 Consistent with our finding that AKT2 promotes the differentiated phenotype, mice with germ-line deletion of Akt2 are more susceptible to abdominal aortic aneurysm in an angiotensin II infusion model, characterized by reductions in contractile protein expression. 24 This study also noted AKT2-dependent regulation of MMP-9 (matrix metalloproteinase-9) and TIMP1 (tissue inhibitor of metalloproteinases 1). We did not detect any obvious changes in collagen expression between WT and SM-Akt2 −/− mice post-injury. Although matrix remodeling enzymes were not directly assessed in our experiments, it is possible that these proteins additionally contribute to the intimal hyperplastic phenotype or the enlarged uninjured femoral artery lumen area we observe with AKT2 deficiency. The role of AKT2 has also been assessed in atherosclerosis, but germ-line knockouts complicate interpretation because of the multiple cell types that contribute to this disease, 46 including an antiinflammatory phenotype in Akt2 −/− macrophages. 47 These studies underscore the complex interplay of cell types in vascular pathologies and the importance of investigating both global and tissue-specific functions of AKT isoforms. FOXO1, FOXO3, and FOXO4 are expressed in human SMC. 32 These transcription factors can bind to regulatory elements with a core binding sequence of TGTTT. 48 We have identified FOXO4 as being specifically regulated by mTORC1 inhibition and AKT2. In preliminary experiments, we found that rapamycin induced phosphorylation of FOXO4 but not FOXO1 and FOXO3 (data not shown). Rapamycin promoted FOXO4 exclusion from the nucleus, and this required AKT2 but not AKT1. It is known that FOXO4 (but not FOXO1 or FOXO3) interacts with both MYOCD and SRF (serum response factor) proteins to inhibit MYOCD-dependent contractile gene expression in SMC. 30 More recently, it was shown that knockdown of FOXO proteins could augment MYOCD mRNA levels and that FOXO3 binding to the MYOCD promoter was PI3K-dependent. 32 We now report that FOXO4 directly binds and negatively regulates the native MYOCD promoter in an AKT2-dependent manner. Forkhead family members are well-known AKT substrates, but there is limited information on specific effects of AKT isoforms, 21 and studies in HeLa cells 49 and fibroblasts 50 indicate no specificity among AKT isoforms for FOXO1 or FOXO3.
49 AKT2-specific regulation of FOXO4 in SMC could potentially be conferred by differences in kinase/ substrate subcellular localization, binding partners, or posttranslational modifications. Notably, we demonstrate that Myocd is an AKT2-dependent target of rapamycin signaling, even in mature, uninjured vessels. MYOCD also has potent antiproliferative effects in SMC and cancer cells. 22, 51 In addition to inhibiting MYOCD, FOXO4 can contribute to SMC migration by promoting MMP-9 expression. 29 Importantly, Foxo4 deletion attenuated intimal hyperplasia in a carotid ligation model. 29 It is likely that the ability to repress FOXO4 and promote expression of MYOCD contributes to the potent antihyperplastic effects of rapamycin in DES.
The AKT pathway regulates many cellular processes through hundreds of substrates. Many substrates are common to all 3 AKT isoforms, but some isoform-specific substrates have been identified as well. 50 The potent effects of AKT2 on SMC phenotype likely involve coordinate regulation of multiple substrates. In addition to AKT2 transcriptional regulation of MYOCD via FOXO4 suppression, we recently identified the transcription factor GATA-6 (GATA-binding protein 6) as an AKT2-specific substrate that promotes SMC differentiation.
23 AKT2-dependent phosphorylation promoted GATA-6 protein stability and DNA-binding activity to induce contractile gene expression. GATA-6 also regulates transcriptional expression of p21 cip , which likely contributes to rapamycin's AKT2-dependent antiproliferative effect in SMC. Notably, GATA-6 can act synergistically with MYOCD. 52 Interestingly, neighboring FOXO-and GATA-binding elements are found in the TIMP1 promoter, and AKT2 has been proposed to relieve FOXO repression of GATA-1 at this promoter in SMC. 24 These data collectively suggest multiple levels of interaction between AKT2-regulated transcription factors. It is likely that AKT2 may regulate other transcriptional and epigenetic factors in addition to FOXO4, MYOCD, and GATA-6 to coordinately control proliferation, migration, extracellular matrix remodeling, and differentiation in SMC.
Our findings suggest a model ( Figure XIVB in the onlineonly Data Supplement) wherein mTORC1 inhibition with rapamycin or its analogs leads to a selective activation of the AKT2 isoform, by relieving the mTORC1-dependent negative regulatory inputs to the IRS-1/PI3K/AKT pathway. 16 This AKT2 activation promotes the phosphorylation and nuclear exclusion of FOXO4. FOXO4 repression enhances MYOCD expression and activity, by inhibiting FOXO4 binding to the MYOCD promoter, as well as by relieving the inhibitory protein-protein interaction between FOXO4 and MYOCD. 30 MYOCD then promotes contractile protein expression and inhibits SMC proliferation. It is likely that AKT2 exerts a concerted prodifferentiation, antiproliferative response through coordinate regulation of transcriptional regulators including FOXO4, MYOCD, and GATA-6. 23 Although stents eluting rapamycin or its analogs are highly efficacious, treatment of diabetic patients remains a challenge because this population develops more complex coronary artery atherosclerotic disease, and DES are less effective in diabetic patients. 53 AKT2 is enriched in insulinresponsive tissues, and mice with germ-line Akt2 deletion are insulin-resistant. 20 Our global Akt2 −/− mice indeed develop hyperglycemia with aging but, importantly, were not hyperglycemic at the time of our experiments. Our work implicates smooth muscle autonomous functions of AKT2 and, importantly, suggests a potential mechanism for the reduced efficacy of rapamycin analog DES in diabetic patients, 53 because insulin resistance would impair the rapamycin-induced feedback activation of AKT2 in vascular smooth muscle, which is necessary for the therapeutic effect of mTORC1 inhibition. This suggests that targeting SMC phenotypic modulation at a step downstream of AKT2 could be advantageous for future drug development.
